COVID-19 时代和 GLP-1 RA 时代：当全球悲剧的黄昏与神奇疗法的黎明同时到来时，这是否是一种复兴？

IF 2.1 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Medical hypotheses Pub Date : 2024-11-08 DOI:10.1016/j.mehy.2024.111516

Deepak Gupta , Berhane Seyoum , Sarwan Kumar , Shushovan Chakrabortty

{"title":"COVID-19 时代和 GLP-1 RA 时代：当全球悲剧的黄昏与神奇疗法的黎明同时到来时，这是否是一种复兴？","authors":"Deepak Gupta , Berhane Seyoum , Sarwan Kumar , Shushovan Chakrabortty","doi":"10.1016/j.mehy.2024.111516","DOIUrl":null,"url":null,"abstract":"<div><div>The hypothesis is that the world should explore to either validate or refute whether glucagon-like peptide–1 receptor agonists (GLP-1 RAs) are drawing some if not all of their all-rounder multisystem capacities in general and their weight-reducing capabilities in particular as catalyzed by natural and/or vaccine-induced immunities against SARS-CoV-2 and their variants implicated as the causative agents for onset and evolution of COVID-19 pandemic globally. The simplest initial exploration could be healthcare systems running queries in their historical databases to assess whether patients who have been receiving GLP-1 RAs since before the pandemic are reporting significantly larger weight-loss since after the pandemic, and if it is so, then whether those significant results could be validated with laboratory and basic research to demonstrate antibodies against SARS-CoV-2 acting as catalysts for larger weight-loss with GLP-1 RAs.</div></div>","PeriodicalId":18425,"journal":{"name":"Medical hypotheses","volume":"194 ","pages":"Article 111516"},"PeriodicalIF":2.1000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"COVID-19 era and GLP-1 RA era: Is it a renaissance when the dusk of global tragedy co-occurring with the dawn of magical remedy?\",\"authors\":\"Deepak Gupta , Berhane Seyoum , Sarwan Kumar , Shushovan Chakrabortty\",\"doi\":\"10.1016/j.mehy.2024.111516\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The hypothesis is that the world should explore to either validate or refute whether glucagon-like peptide–1 receptor agonists (GLP-1 RAs) are drawing some if not all of their all-rounder multisystem capacities in general and their weight-reducing capabilities in particular as catalyzed by natural and/or vaccine-induced immunities against SARS-CoV-2 and their variants implicated as the causative agents for onset and evolution of COVID-19 pandemic globally. The simplest initial exploration could be healthcare systems running queries in their historical databases to assess whether patients who have been receiving GLP-1 RAs since before the pandemic are reporting significantly larger weight-loss since after the pandemic, and if it is so, then whether those significant results could be validated with laboratory and basic research to demonstrate antibodies against SARS-CoV-2 acting as catalysts for larger weight-loss with GLP-1 RAs.</div></div>\",\"PeriodicalId\":18425,\"journal\":{\"name\":\"Medical hypotheses\",\"volume\":\"194 \",\"pages\":\"Article 111516\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical hypotheses\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0306987724002597\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical hypotheses","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0306987724002597","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

我们的假设是，全世界都应该探索胰高血糖素样肽-1 受体激动剂（GLP-1 RAs）是否正在通过天然免疫和/或疫苗诱导免疫来抵御 SARS-CoV-2 及其变种（被认为是 COVID-19 在全球范围内爆发和演变的致病因子），从而在总体上（如果不是全部的话）发挥其全面的多系统能力，特别是减轻体重的能力。最简单的初步探索可以是医疗保健系统在其历史数据库中进行查询，以评估自大流行前就开始接受 GLP-1 RAs 的患者是否报告自大流行后体重明显减轻，如果是，那么这些重要结果是否可以通过实验室和基础研究进行验证，以证明针对 SARS-CoV-2 的抗体是 GLP-1 RAs 带来更大体重减轻的催化剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

COVID-19 era and GLP-1 RA era: Is it a renaissance when the dusk of global tragedy co-occurring with the dawn of magical remedy?

The hypothesis is that the world should explore to either validate or refute whether glucagon-like peptide–1 receptor agonists (GLP-1 RAs) are drawing some if not all of their all-rounder multisystem capacities in general and their weight-reducing capabilities in particular as catalyzed by natural and/or vaccine-induced immunities against SARS-CoV-2 and their variants implicated as the causative agents for onset and evolution of COVID-19 pandemic globally. The simplest initial exploration could be healthcare systems running queries in their historical databases to assess whether patients who have been receiving GLP-1 RAs since before the pandemic are reporting significantly larger weight-loss since after the pandemic, and if it is so, then whether those significant results could be validated with laboratory and basic research to demonstrate antibodies against SARS-CoV-2 acting as catalysts for larger weight-loss with GLP-1 RAs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Medical hypotheses 医学-医学：研究与实验

CiteScore

10.60

自引率

2.10%

发文量

167

审稿时长

60 days

期刊介绍： Medical Hypotheses is a forum for ideas in medicine and related biomedical sciences. It will publish interesting and important theoretical papers that foster the diversity and debate upon which the scientific process thrives. The Aims and Scope of Medical Hypotheses are no different now from what was proposed by the founder of the journal, the late Dr David Horrobin. In his introduction to the first issue of the Journal, he asks ''what sorts of papers will be published in Medical Hypotheses? and goes on to answer ''Medical Hypotheses will publish papers which describe theories, ideas which have a great deal of observational support and some hypotheses where experimental support is yet fragmentary''. (Horrobin DF, 1975 Ideas in Biomedical Science: Reasons for the foundation of Medical Hypotheses. Medical Hypotheses Volume 1, Issue 1, January-February 1975, Pages 1-2.). Medical Hypotheses was therefore launched, and still exists today, to give novel, radical new ideas and speculations in medicine open-minded consideration, opening the field to radical hypotheses which would be rejected by most conventional journals. Papers in Medical Hypotheses take a standard scientific form in terms of style, structure and referencing. The journal therefore constitutes a bridge between cutting-edge theory and the mainstream of medical and scientific communication, which ideas must eventually enter if they are to be critiqued and tested against observations.